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Background: Leukocytes containing opioid peptides locally control inflammatory pain. In the early phase of complete
Freund’s adjuvant (CFA)-induced hind paw inflammation, formyl peptides (derived e.g. from Mycobacterium butyricum)
trigger the release of opioid peptides from neutrophils contributing to tonic basal antinociception. In the later phase
we hypothesized that toll-like-receptor-(TLR)-4 activation of monocytes/macrophages triggers opioid peptide release
and thereby stimulates peripheral opioid-dependent antinociception.
Results: In Wistar rats with CFA hind paw inflammation in the later inflammatory phase (48–96 h) systemic leukocyte
depletion by cyclophosphamide (CTX) or locally injected naloxone (NLX) further decreased mechanical and thermal
nociceptive thresholds. In vitro β-endorphin (β-END) content increased during human monocyte differentiation as well
as in anti-inflammatory CD14+CD16- or non-classical M2 macrophages. Monocytes expressing TLR4 dose-dependently
released β-END after stimulation with lipopolysaccharide (LPS) dependent on intracellular calcium. Despite TLR4
expression proinflammatory M1 and anti-inflammatory M2 macrophages only secreted opioid peptides in
response to ionomycin, a calcium ionophore. Intraplantar injection of LPS as a TLR4 agonist into the inflamed
paw elicited an immediate opioid- and dose-dependent antinociception, which was blocked by TAK-242, a
small-molecule inhibitor of TLR4, or by peripheral applied NLX. In the later phase LPS lowered mechanical and
thermal nociceptive thresholds. Furthermore, local peripheral TLR4 blockade worsened thermal and mechanical
nociceptive pain thresholds in CFA inflammation.
Conclusion: Endogenous opioids from monocytes/macrophages mediate endogenous antinociception in the late
phase of inflammation. Peripheral TLR4 stimulation acts as a transient counter-regulatory mechanism for inflammatory
pain in vivo, and increases the release of opioid peptides from monocytes in vitro. TLR4 antagonists as new treatments
for sepsis and neuropathic pain might unexpectedly transiently enhance pain by impairing peripheral opioid analgesia.
Keywords: Toll like receptors, Analgesia, Inflammatory pain, Endogenous opioidsBackground
Inflammatory pain is elicited by proalgesic mediators e.g.
proinflammatory cytokines, prostaglandins, and bradyki-
nin [1,2]. Recently, toll like receptors (TLR) have been
identified as important mediators in inflammatory as well
as neuropathic pain [3,4]. TLRs are pattern recognition re-
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stated.bacteria or viruses. Direct stimulation of TLR with ex-
ogenous ligands e.g. lipopolysaccharide (LPS) - or possibly
mycobacteria binding TLR4 - can provoke pain [5-7]. Pain
is decreased in TLR2 or −4 deficient mice with neuro-
pathic lesions [8,9], which implies TLR activation via en-
dogenous ligands like heat shock proteins. Most of the
proalgesic action of TLRs is due to sensory neurons de-
tecting and relaying pain messages in response to local
peripheral inflammation, mostly attributed to the spinal
level including activation of microglia and sensory neurons
[3]. Peripheral mechanisms are less studied so far. Sincetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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for treatment sepsis as well as neuropathic pain a care-
ful evaluation of these is important for the design of the
studies [10].
Intraplantar injection of heat inactivated Mycobacterium
butyricum in oily solution (“complete Freund’s adjuvant,
CFA”) elicits inflammatory pain resulting in spontaneous
activity of nociceptive Aδ and C nerve fibers [1,11]. The
net intensity of inflammatory pain is not only dependent
on proalgesic mediators, but is counterbalanced by en-
dogenous analgesic mediators including opioid peptides
[12]. In early CFA inflammation neutrophils predominate.
Stimulation of neutrophils by chemokines like CXCL2/3
or bacterial components (formyl peptides) induces re-
lease of opioid peptides like β-endorphin (β-END) and
met-enkephalin (Met-ENK). This counterbalances hyper-
algesic mediators and induces peripheral opioid-mediated
antinociception in models of neuropathic, inflamma-
tory, arthritic, bone cancer and visceral pain [13-17].
So far T-lymphocytes and neutrophils have been stud-
ied in detail [18-20]. Antigen-specific and stimulated
T-cells increase the synthesis of met-enkephalin and
elicit antinociception in adoptive transfer modes in
arthritic pain. Mycobacteria stimulate neutrophils to
secret of opioid peptides via formyl peptide receptors,
although we expected stimulation via TLR2 and TLR4, be-
cause these are the primary target receptors of mycobac-
teria [21]. However, monocytes are not stimulated to
release opioid peptides by mycobacteria in vitro although
they express formyl peptide receptors. Monocytes/macro-
phages are the major opioid containing leukocyte popula-
tion after 48 h CFA inflammation [22]. Moderate depletion
of monocytes/macrophages by clodronate liposomes re-
duces swim stress-induced peripheral opioid-mediated an-
algesia [23]. To sum up, the role of opioid-containing
monocytes/macrophages has not been clearly defined in in-
flammatory pain.
Monocytes are divided in classical pro-inflammatory
CD14+CD16+ and anti-inflammatory CD14+CD16-
monocytes. CD14+CD16+, in contrast to CD14+ non-
expressing CD16 classical monocytes, represent <10%
of the total monocytes in normal blood but increase in
various inflammatory diseases [24]. Monocytes migrate
into the tissue and differentiate into macrophages.
In vitro macrophages can be functionally polarized by
granulocyte macrophage colony-stimulating factor
(GM-CSF) into M1 (proinflammatory, antimicrobial)
and by macrophage colony-stimulating factor (M-CSF)
and interleukin-10 (IL-10) into M2 (alternatively acti-
vated) for tissue repair. TLR agonists and lipopolysac-
charide (LPS) are important activators of monocytes
and macrophages. In addition macrophages express a
variety of other surface markers in part of unknown
function including PM-2 K and 25 F9 [25].The present study examines molecular mechanisms of
peripheral opioid-mediated analgesia in late CFA inflam-
mation. Specifically, we investigated i) the subtypes of
monocytes and macrophages for in vitro opioid peptide
release after TLR4 stimulation and ii) the characteristics of
LPS-induced antinociception and iii) involvement of TLR4
in the generation of tonic peripheral antinociception.
Results
Immune cells and peripheral opioids contribute to
baseline analgesia in inflammatory pain
Treatment with cyclophosphamide (CTX) significantly de-
pletes immune cells in the blood in Wistar rats [26]. In
rats with 96 h CFA-induced hind-paw inflammation im-
mune cell depletion with CTX reduced RP1+CD45+-neu-
trophils by 96.6% (340.0 ± 84.2 vs. 11.5 ± 1.9 × 103 cells),
ED1+CD45+-macrophages by 97.3% (806.8 ± 145.1 vs.
22.0 ± 3.0 × 103 cells) and 3E7+CD45+-opioid containing
leukocytes by 93.1% (455.8 ± 103.0 vs. 31.4 ± 5.4 × 103
cells) in the inflamed paw as previously measured by flow
cytometry [27]. CTX treatment further lowered mechan-
ical (Figure 1A) and thermal (Figure 1B) nociceptive
thresholds in the inflamed paw beginning on day one after
intraplantar injection of CFA while the contralateral paws
were unaffected. However, the kinetics of the effect was
different: Mechanical nociceptive thresholds steadily de-
creased up to 48 h and then remained stable in CTX
treated rats. Thermal nociceptive thresholds were similar
between CFA ±CTX as well as CFA only rats at 24 h, but
in CFA only rats paw withdrawal latency progressively
rose over time, while CFA ± CTX remained low. No
change in paw pressure thresholds or paw withdrawal la-
tencies was previously seen in rats treated CTX alone [28].
Paw volume was significantly less in early inflammation
(24 h post CFA) in immunodepleted rats, but paws were
significantly more swollen in late inflammation (72–96 h
post CFA) in rats with CTX treatment (Figure 1C). No
change of paw volume was observed in the contralateral
paw.
Intraplantar injection of naloxone (NLX) in a low dose
can evaluate the contribution of peripheral opioid receptors
because central receptors are not blocked [14,29]. Injection
of NLX (1.8 μg) 48 and 96 h after induction of inflamma-
tion further significantly reduced thermal (Figure 1D, E)
and mechanical (Figure 1F, G) nociceptive thresholds. No
change in paw withdrawal latency or paw pressure thresh-
old was seen in the contralateral paw (Figure 1D-G) as well
as by injection of solvent (saline) only in previous paw with-
drawal latency experiments [14] as well as current paw
pressure threshold measurements (CFA 48 h saline injec-
tion: basal 43.6±1.2 g; treated 43.0±1.1 g; CFA 96 h saline
injection: basal 42.7±1.3 g; treated 44.2±1.1 g). During CFA
inflammation neutrophils are the predominant source of
opioid peptides in early stages of inflammation (2–6 h)
Figure 1 Increased hyperalgesia by leukocyte depletion or peripheral opioid receptor blockade in inflammatory pain. Male Wistar rats
were leukocyte depleted with cyclophosphamide (CTX, 100 mg/kg and 50 mg/kg BW on day −3, -1 and 1). Complete Freund’s adjuvant (CFA)
was injected i.pl. at day 0. Paw pressure thresholds (A), paw withdrawal latency (B) and paw volume (C) were measured at 0, 24, 48, 72 and 96 h
after induction of inflammation in the ipsilateral (ipsi) and contralateral (contra) paw (no CTX n = 3–6, CTX n = 6–8,. * p < 0.05 vs. 0 h, # p < 0.05 vs.
CFA ipsilateral, Two Way RM ANOVA, Student Newman Keuls). CTX alone did not change paw pressure thresholds [28]. (D, F) After 48 h and
(E, G) 96 h of CFA hind-paw inflammation the opioid receptor antagonist naloxone (NLX, 0.56 ng) was injected i.pl. Thermal (D, E) and mechanical
(F, G) nociceptive thresholds were determined before and 10 min after treatment and compared to contralateral side (n = 4–6, * p < 0.05, * vs. basal,
Two Way ANOVA, Student-Newman-Keuls). No change was seen in saline injected rats before [14]. All data are presented as MEAN± SEM.
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stages (96 h) [22,23]. Therefore, we hypothesized that
monocytes and macrophages could be the source of periph-
eral opioid mediated analgesia.
Macrophage subpopulation in the inflamed paw
In inflammatory infiltrate 4 d after CFA inflammation
consisted of neutrophils and macrophages. Previously only
a small number of infiltrating T-lymphocytes was ob-
served by flow cytometry quantification (~5%) [22]. Since
markers for proinflammatory M1 and antiinflammatory
M2 macrophages are less defined in rats we used ED1(CD68) and ED2 (CD163) as comparable markers [30].
CD163 is a scavenger receptor for the endocytosis and in-
duced by antiinflammatory cytokines like IL-10. CD68 is a
glycoprotein which binds to low density lipoprotein. In
the inflammatory infiltrate in the paw after 4 d of in-
flammation the number of neutrophils (RP-1+CD45+)
was significantly lower compared to CD68+CD45+ M1
proinflammatory or CD163+CD45+ M2 antiinflammatory
cells (Figure 2A, B) while the percentages of CD68+CD45+
and CD163+CD45+ cells in the infiltrate were comparable.
In conclusion, we did not observe a predominance of M2
vs. M1 macrophages. In the next step, we studied the
Figure 2 Characterization of infiltrating leukocytes in the inflamed paw. Rats were injected with CFA for 4 d. (A) Cells suspensions from
subcutaneous paw tissue were first stained for CD45 to gate on hematopoetic cells (x-axis: forward scatter [size], y-axis: CD45-PerCp-Cy5). (B)
The dot plot (x-axis: FITC, y-axis: PE) shows unstained controls from cells gated on CD45. CD45+ cells were stained for RP-1 (neutrophils), CD68
(M1, proinflammatory macrophages) (C, x-axis: CD68-FITC, y-axis: RP-1-PE) as well as and CD163 (M2, antiinflammatory macrophages) (D, x-axis:
CD163-FITC, y-axis: PE). Representative examples are shown (n = 8). (E) The percentage of infiltrating leukocyte subpopulations were measured
(n = 8, ANOVA on Ranks, Student-Newman-Keuls). (F-I) TLR4-Expression in the paw was analyzed in leukocytes gated on CD45+ (F, x-axis:
forward scatter, y-axis: CD45-PerCp-Cy5 fluorescence). TLR4-Expression in CD68+ M1 macrophages (H, x-axis: CD68-FITC, y-axis: TLR4-PE) and in
CD163+ M2 macrophages (I, x-axis: CD163-FITC, y-axis: TLR4-PE) and compared to the unstained control (G, unstained control, x-axis: FITC
fluorescence, y-axis: PE fluorescence). Representative examples are shown (n = 2).
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The majority of CD45+ (>80%) cells in the paw expressed
TLR4. Indeed, >75% of the CD68+CD45+ and >90% of the
CD163+CD45+ cells were TLR4+.CD14+CD16- anti-inflammatory monocytes contain more
β-END released by TLR4 stimulation
To evaluate release of opioid peptides and specifically β-
END in vitro we used human monocytes due to availability
in larger quantities. Incubation of purified CD14+ human
monocytes with LPS, a potent agonist stimulating TLR4, in-
duced a dose-dependent release of β-END after 15, 60 and
120 min (Figure 3A). A maximal significant release was ob-
served with 10 μg/ml LPS resulting in a twofold increase.
No release of β-END was seen after stimulation with
Pam3CSK4 stimulating TLR2 independent of the time
point (Figure 3B). In the next step we evaluated mono-
cyte subpopulations: pro-inflammatory CD14+CD16+
and anti-inflammatory CD14+CD16- purified by mag-
netic beads. Both CD14+CD16+ as well as CD14+CD16-
monocytes expressed TLR2 and TLR4 on the surface(Figure 3C). However, pro-inflammatory CD14+CD16+
contained significantly less β-END then anti-inflammatory
CD14+CD16- monocytes (Figure 3D). Both populations
were able to release β-END after stimulation of LPS after
15 min (Figure 3E, F).β-END release by TLR4 stimulation is calcium-dependent
To study intracellular mechanism of opioid peptide release
from monocytes we first analyzed β-END release after
stimulation with the calcium ionophore ionomycin. Iono-
mycin elicited a significant release of β-END (Figure 4A) in
the supernatant by 59.7% as well as a translocation of opi-
oid peptides containing vesicles to the membrane as seen
by confocal imaging (Figure 4B) indicating calcium-
dependent release. To evaluate the mechanisms of LPS-
dependent release, monocytes were preincubated with
BAPTA-AM (Figure 4C), an intracellular Ca2+ chelator or
2-APB (Figure 4D), an IP3 receptor antagonist. Both treat-
ments significantly inhibited LPS-induced β-END release.
In addition, preincubation with BAPTA-AM as well as 2-
APB significantly lowered release below baseline release.
Figure 3 Release of opioid peptides from monocytes in response to TLR4 but not TLR2 stimulation. (A, B) Monocytes were isolated from
human buffy coats and purified for CD14. Release of β-endorphin (β-END) was quantified after incubation for 15 or 120 min with different doses
of LPS or Pam3CSK4 (n = 7–9, * p < 0.05, One way RM ANOVA, Student-Newman-Keuls). (C) Monocytes were separated into CD14
+CD16- and
CD14+CD16+ monocytes. Expression of TLR2 (green line) and TLR4 (red line) was analyzed using flow cytometry in both populations. Isotype
controls are shown (black line) (representative example, n = 3). (D) β-END content after lysis of unstimulated cells was measured by ELISA in these
populations, CD14+CD16- (black) and CD14+CD16+ (black striped) monocytes (n = 8, * p < 0.05 paired t-test) (E,F) CD14+CD16- and CD14+CD16+
monocytes were stimulated for 15 min with 10 μg/ml LPS (red) compared to stimulation with solvent medium (black). β-END was analyzed in
the supernatant (n = 8, * p < 0.05, paired t-test). All data are presented as MEAN ± SEM.
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LPS is dependent on the availability of intracellular calcium.
In vitro differentiation of monocytes into macrophages
increases β-END content in anti-inflammatory
M2-macrophages
When monocytes migrate into the tissue they differenti-
ate into tissue macrophages. In vitro human monocytesdifferentiated into classical M1 macrophages by
addition of GM-CSF and non-classical M2 macrophages
by addition of M-CSF and IL-10 (Figure 5A). Human
M1 macrophages expressed high levels of CD14 (86.5%)
and low levels of CD16 (2.1%). In contrast human M2
macrophages were highly positive for both, CD14
(91.9%) and CD16 (84%). PM-2 K and 25 F9 are markers
to characterize macrophages [25] PM-2 K is hardly
Figure 4 Calcium requirement of TLR4-stimulated β-END release. (A) Release of β-END in the supernatant was quantified after incubation of
CD14+ monocytes for 15 min with 10 μM ionomycin (iono) or medium (control) (n = 3, * p < 0.05, paired t-test). (B) CD14+ monocytes were
stimulated as described before and stained on cytospins using a ββ-END antibody (red) and confocal analysis (representative example, n = 3).
(C-E) CD14+ monocytes were preincubated with BAPTA-AM (100 μM, n = 24–28, * p < 0.05, One Way RM ANOVA, Student-Newman-Keuls, C),
2-APB (100 nM, n = 11 * p < 0.05, One Way RM ANOVA, Student-Newman-Keuls, D) for 10 min before the addition of 10 μg/ml LPS for 15 min.
Secretion of β-END was quantified in the supernatant. All data are presented as MEAN ± SEM.
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on most of M2 macrophages (mean: 77 ± 0.05%). 25 F9
is expressed on M1 macrophages as well as M2 macro-
phages (mean: 21.5 ± 0.06% vs. 66 ± 0.11%, respect-
ively). TLR2 and TLR4 are expressed albeit in lower
levels on M1 macrophages (TLR2: 21% and TLR4:18%)
compared to M2 macrophages (TLR2: 60% and
TLR4:14%) (Figure 5B).
Differentiation into human macrophages from the
same donor resulted in an increase in opioid peptide
content in M1 macrophages by 15% and significantly in
M2 macrophages by 27.2% (Figure 5C). Ionomycin elic-
ited secretion of β-END after 15 min (M1 macrophages
by 45% and M2 macrophages 46.5%). In comparison,
stimulation using LPS stimulated only a small release
after 15 min (M1 macrophages by 5% and M2 macro-
phages 7.1%) (Figure 5D). Longer incubation times up to
120 min did not result in more release over time (data
not shown). In summary, classical M1 macrophages pro-
duce less opioid peptides and expressed less TLR2 and
TLR4 compared to non-classical M2 macrophages. Both
subpopulations released β-endorphin in response to
ionomycin and only minor amounts in response to LPS.TLR4-dependent antinociception of LPS in CFA
inflammation and tonic analgesia
In the last step, we evaluated the role of LPS and TLR4
in vivo in inflammatory pain. Rats with 4 d CFA hind paw
inflammation were injected i.pl. with different doses of
LPS. Mechanical nociceptive thresholds dose-dependently
and significantly increased immediately after i.pl. LPS
treatment indicating an antinociceptive property of LPS
(Figure 6A). The optimal dose of LPS increased thermal
nociceptive as well as mechanical thresholds (Figure 6B,
C). Animals treated with LPS i.pl. did not show any signs
of general illness and had no significant changes in mech-
anical or thermal nociceptive thresholds in the contralat-
eral paw (Figure 6B, D). LPS-induced mechanical and
thermal antinociception lasted up to 30 min and returned
to baseline after 120 min. The antinociceptive effect of
LPS was mediated by peripheral opioid receptors and opi-
oid peptides (Figure 6D). Treatment with NLX i.pl. as well
as anti-β-endorphin antibodies using peripheral selective
doses [14] blocked LPS-induced thermal antinociception.
No change in pain behavior was observed in contralateral
paws. After the initial phase of antinociception LPS then
significantly lowered thermal (Figure 6B) and mechanical
Figure 5 Content and release of β-END in macrophage differentiation. CD14+ monocytes were in vitro differentiated into M1 macrophages
with GM-CSF (left column) and M2 macrophages with M-CSF and IL-10 (right column). Surface marker expression of CD16, CD14 as well as
PM-2 K and 25 F9 as well as TLR2 and TLR4 were evaluated by flow cytometry. (A) Expression of CD16, CD14 as well as PM-2 K and 25 F9 on M1
and M2 macrophages as well as (B) TLR4 (red line) and TLR2 (green line). Representative examples were shown; isotype controls are depicted in
grey lines (representative examples). (C) CD14+ monocytes (Mono) before differentiation and M1 and M2 macrophages (Mac) from the same
individual after 6–7 d of culture were lysed and intracellular β-END content measured by ELISA (n = 14, * p < 0.05, paired t-test). (D) Release of
β-END after incubation with 10 μM ionomycin (iono) or 10 μg/ml lipopolysaccharide (LPS) for 15 min from M1 and M2 macrophages was quantified in
the supernatant (n = 21–24 for LPS and n = 7–8 for ionomycin, * p < 0.05, paired t-test). All data are presented as MEAN ± SEM.
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algesia was unaffected by local anti-β-endorphin, but local
naloxone reversed hyperalgesia.
To analyze the involvement of TLR4 in LPS-induced
antinociception rats were concomitantly treated with a
small molecule inhibitor of TLR4, TAK-242/resatorvid.
Higher doses completely blocked LPS-induced mechanical
(Figure 6E) and thermal (Figure 6F) antinociception andresulted in a further decrease of baseline hyperalgesia after
120 min. Nociceptive thresholds were unaffected in contra-
lateral paws. In vitro TAK-242 was dose-dependently able
to completely block LPS-induced β-END release in undif-
ferentiated CD14+ human monocytes (Figure 7A). In the
last step we wanted to determine of role of TLR4 in the
generation of inflammatory hyperalgesia. The effect of
TLR4 inhibition in vivo in rats with CFA inflammation on
Figure 6 Opioid-dependent LPS-induced antinociception in inflammatory pain. All rats were injected with CFA i.pl. 4 d before further
treatment. (A) Mechanical nociceptive thresholds were measured before and 5–120 min after injection of 100 μl LPS (0.01-1 μg) i.pl. (n = 6, * vs. 0 min,
p < 0.05, Two way RM ANOVA, Student-Newman-Keuls). (B, C) Rats were treated with 1 μg LPS i.pl. and thermal nociceptive as well as mechanical
thresholds were determined after indicated time points (n = 6, * vs. 0 min, * p < 0.05, Two way RM ANOVA, Student-Newman-Keuls). (D) Thermal
nociceptive thresholds were measured after 5 min – 1 d in rats after 1 μg LPS i.pl. and as well as NLX (0.56 ng) or anti-β-endorphin antibody (anti-END,
2 μg) compared to control antibody (IgG2 μg, all black symbols). Contralateral paws from rats in each treatment group are shown for comparison
(white symbols). (E,F) The effect of the small molecule TLR4 inhibitor, TAK-242 i.pl. (1, 10 μg/ml) on LPS-induced antinociception was evaluated in
mechanical and thermal nociceptive thresholds. (E) Paw pressure thresholds in inflamed paws (ipsi, black symbols) were obtained after 5–120 min
(n = 3–7). (F) Thermal nociceptive thresholds were measured in inflamed paws (ipsi, black symbols) rats after 1 μg LPS and 10 μg TAK-242 i.pl. at
indicated time points compared to solvent (n = 6, * vs. 0 min, p < 0.05, Two way RM ANOVA, Student-Newman-Keuls). Contralateral (contra) paws are
shown seen for comparison (white symbols). The data from the treatment group LPS + control IgG (black circles) is displayed for comparison from
graph 6D. All data are presented as MEAN± SEM. always n = 6 except when indicated otherwise, * vs. 0 min, p < 0.05, Two way RM ANOVA,
Student-Newman-Keuls).
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olds was analyzed. Treatment with TAK-242 resulted
in a pronounced lowering of thermal nociceptive
thresholds immediately after injection in rats with CFA
inflammation, which lasted up to 30 min and returned
to baseline after 120 min (Figure 7B). No change in thecontralateral paws was observed in these animals.
Mechanical nociceptive thresholds also dropped but
with a different kinetics (Figure 7C). The maximal in-
crease in hyperalgesia was seen after 240 min and
returned to baseline after 1 day. Again contralateral
paws were unaffected.
Figure 7 Hyperalgesia by TLR4 blockade in inflammatory pain. (A) Purified undifferentiated CD14+ human monocytes were incubated with
10 μg/ml LPS and a TLR4 inhibitor (TAK-242) in different doses. β-END release was quantified in the supernatant after 15 min (n = 6, * vs. LPS,
*p <0.05, One Way RM ANOVA, Student-Newman-Keuls). (B, C) Rats with 4 d CFA inflammation were treated with TAK-242 i.pl. (1 μg, black
triangle, and 10 μg, black square) and paw withdrawal latency (B) or paw pressure thresholds (C) were measured subsequently at indicated time
points and compared to solvent (5% DMSO, black circle) in the inflamed paws (ipsilateral, ipsi). Paw pressure thresholds and paw withdrawal
latencies from contralateral (contra, white symbols) paws are shown for comparison (n = 3–6, * vs. 0 min, * p < 0.05, Two way RM ANOVA,
Student-Newman-Keuls). All data are presented as MEAN ± SEM.
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In the present study, peripheral opioid-dependent anal-
gesia in the late phase is mediated via TLR4-stimulation
of monocytes/macrophages releasing opioid peptides
binding to peripheral opioid receptors. In vitro, monocytes
and macrophages with an anti-inflammatory phenotypesynthesize more opioid peptides. β-END is released from
monocytes dependent on calcium through stimulation
with the TLR4-agonist LPS. Intraplantar LPS injection
in vivo immediately elicits opioid- and TLR4-dependent
antinociception in CFA inflammation. In the later phase
LPS further lowers nociceptive thresholds. Application of
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baseline thermal and mechanical hyperalgesia.
Peripheral opioid mediated analgesia
Different subpopulations of immune cells contribute to
peripheral opioid-mediated antinociception. Neutrophils
play an important role in the first phase because depletion
of neutrophils in CFA inflammation or skin incision in-
creases thermal hyperalgesia but not mechanical hyper-
algesia [13-15]. Neutrophils are activated via chemokines
or formyl peptides to secrete opioid peptides. Mobilization
of neutrophils using GM-CSF treatment in CFA inflam-
mation has no effect on mechanical hyperalgesia [31] and,
on the contrary, even increases pain in neuropathic pain
models [32].
Opioid-producing T cells are important soldiers in the
battle against pain in different models including inflamma-
tory pain [18,33] neuropathic pain [19] and visceral pain
[20]. In CFA-induced arthritis antigen-specific activated,
but not resting CD4+ T lymphocytes are responsible for
the spontaneous relief of inflammation-induced pain fol-
lowing Ag challenge [18,33]. Analgesia was observed by
transferring effector CD4+ T lymphocytes with Th1 or
Th2 phenotype, suggesting that antinociceptive activity is
a fundamental property of effector CD4+ T lymphocytes
irrespective of their effector functions [18]. Similarly, in
immunocompromised mice with chronic constriction
neuropathy transfer of T-cells reverses neuropathic pain at
later stages [19,34].
In later phases of CFA inflammation monocytes/macro-
phages are the major opioid-containing cells. Reduction
(but not depletion) of monocytes/macrophages via clodor-
anate containing liposomes by 30% decreases opioid
dependent swim stress-induced antinociception and has
no effect on baseline hyperalgesia [23]. A higher selective
depletion of monocytes/macrophages was not achieved.
Therefore, we used the unselective immune depletion by
CTX in this study. This treatment further worsened in-
flammatory mechanical hyperalgesia. Local application of
μ-opioid receptor antagonists decreased thermal nocicep-
tive thresholds. In accordance, mechanical nociceptive
thresholds were lowered by intraplantar injection of nalox-
one or anti-β-END antibodies [29]. No change of nocicep-
tive thresholds was observed in contralateral paws in this
study or rats without inflammation in previous studies
[28] arguing against a general proalgesic property of CTX.
Peripheral opioid-dependent analgesia is mostly short-
term possibly because aminopeptidase N or neutral endo-
peptidases produced by leukocytes or peripheral nerves
rapidly degrade opioid peptides [35]. Peripheral opioid-
mediated analgesia lasts only shortly (around 10 min) in
early inflammation when mostly neutrophils are triggered
by chemokines or formyl peptides [13,14]. We now show
that monocyte-based peripheral opioid-mediated analgesiavia LPS lasts longer up to 30 min at 4 d after i.pl. CFA in-
jection. Since both macrophages and neutrophils express
activated aminopeptidase N or neutral endopeptidases we
postulate that the longer duration of antinociception is
due to a more sustained release. In accordance, we found
that 15, 60 and 120 min stimulation of monocytes in vitro
lead to significant opioid peptide release.
Our results are in contrast with a recent publication in
mice with CFA inflammation [36]. In this model tissue in-
jury produced μ-opioid receptor constitutive activity that
repressed spinal nociceptive signaling for months. There-
fore, NLX was able to prolong mechanical hyperalgesia
but naltrexone methobromide, an opioid receptor antag-
onist that cannot cross the blood–brain-barrier, was not
able to worsen mechanical hyperalgesia. In our model we
used a standard peripheral selective dose of NLX. This ex-
cludes the possibility that central or spinal opioid recep-
tors play a role in our model in rats. Also we observed
differences in mechanical and thermal hyperalgesia.
Therefore spinal and peripheral tonic opioid mechanisms
exist but in part with a different kinetic and with different
sensitivities (mechanical or thermal). Tonic opioid anal-
gesia is also seen in other models like arthritic visceral
pain [16] or visceral pain [17,37]. However, most groups
have seen central nervous system effects of tonic opioids
and not peripheral.
In summary, all leukocyte subpopulations contain and
secrete opioid peptides in response to different stimuli. So
far, there is no difference whether they belong to the in-
nate or the specific immune system. Inflammatory pain
and neuropathic pain in different models is worsened in
immunosuppressive states.
Monocyte and macrophage subtypes
In our study we did not find a difference of TLR expression
in CD14+CD16+ compared to CD14+CD16- monocytes in
healthy donors. In contrast, patients with acute myocardial
inflammation, TLR4 were more expressed on circulating
CD14+CD16+ monocytes than on CD14+CD16- monocytes
[24]. Differentiation into M1 or M2 macrophages, however,
decreased TLR2 and TLR4 expression. Functional response
to TLR4 stimulation, specifically opioid peptide release, re-
vealed no difference between pro-and anti-inflammatory
monocytes, although anti-inflammatory monocytes seemed
to contain more opioid peptides. Elevated blood levels of
inflammatory monocytes (CD14+CD16+) are present in pa-
tients with complex regional pain syndrome [38]. Lower
levels of opioid peptide content could support increased
pain in these patients. In vitro differentiated M1 and M2
macrophage were hardly able to release β-END in response
to TLR4 stimulation. This might be partially related to the
decreased levels of TLR4 expression under in vitro culture
conditions, higher amounts of opioid peptides released in
response to “priming” by cytochalasin or the necessity of
Sauer et al. Molecular Pain 2014, 10:10 Page 11 of 15
http://www.molecularpain.com/content/10/1/10co-stimulatory molecule activation [39]. In the inflamed
paw both M1 (CD68+) and M2 (CD163+) macrophages
were found with no obvious predominance of one type.
However, characterization of polarized macrophages in vivo
in the tissue has remained difficult and data have to be
interpreted with caution, because a battery of cell markers
might be necessary to distinguish between these popula-
tions in vivo [30]. Nevertheless, both macrophage subpopu-
lations were highly positive for TLR4. In vitro differentiated
human M1 macrophages were less positive for TLR4. In
summary, TLR4 is expressed on all monocyte and macro-
phage subpopulations to a various extent. TLR4 stimulation
releases opioid peptides, but in vitro differentiated macro-
phages seem to be much less responsive.
TLR4 stimulates two intracellular cascades. The major
one involves MyD88, IL-1R associated kinase (IRAK),
tumor necrosis factor associated factor 6 (TRAF6) and
NFĸB or mitogen-activated proteins kinas (MAPK). Acti-
vation of MAPK pathways causes release of inflammatory
mediators like chemokines [3]. Calcium-dependent pro-
cesses support this. TLR4, -9, and −3 ligands markedly
induce intracellular calcium fluxes and activate CaMKII-
alpha in macrophages [40]. Calcium has been shown to be
essential for opioid peptide release via formyl peptide re-
ceptor of CXCR2 in neutrophils [13,14]. Similar mecha-
nisms seem to be important in monocytes. However, there
are differences in the amount of opioid peptides released
and the duration of release. Monocytes/macrophages re-
lease lower amounts in vitro compared to an up to four-
fold increase in opioid peptide release from neutrophils
after formyl peptide stimulation [14]. In neutrophils, opi-
oid peptide secretion is rapid (after 7 min) with no further
increase, while in monocytes releases is detectable up to
120 min. Similarly in in vivo studies i.pl. injection of for-
myl peptides in 2 h CFA inflammation induces an antino-
ciceptive effect for 10 min [14] while in this study i.pl. LPS
increases mechanical nociceptive thresholds for 30 min in
96 h CFA inflammation.
Role of TLRs in pain
Most of the studies in TLR and pain have concentrated
on the nociceptive processing in the spinal cord. Follow-
ing tissue insult and nerve injury, TLRs (such as TLR2,
TLR3, and TLR4) induce the activation of microglia and
astrocytes and the production of the proinflammatory
cytokines in the spinal cord, leading to the development
and maintenance of inflammatory pain (e.g. serum-
transferred arthritis) and neuropathic pain [3,41,42]. In
neuropathic pain, both the genetically altered mice and
the rats treated with TLR4 antisense oligodeoxynucleo-
tide have a significantly attenuated behavioral hypersen-
sitivity and decreased expression of spinal microglial
markers and proinflammatory cytokines compared to
their respective control groups [8]. This is also observedin rats with bone cancer pain were treated intrathecally
with TLR4 siRNA [43]. Stimulation of murine dorsal root
ganglion neurons with TLR ligands (TLR3, 7, and 9) in-
duced expression and production of proinflammatory
chemokines and cytokines, upregulation of transient
receptor potential vanilloid type 1 (TRPV1), and en-
hanced calcium flux by TRPV1-expressing dorsal root
ganglion neurons [4]. TLR4 is also implicated in spinal
opioid-induced hyperalgesia [44]. Morphine binds to
an accessory protein of TLR4 thereby inducing TLR4
oligomerization and triggering spinal inflammation. In
summary, TLR4 on microglia significantly modulates
several types of pain and morphine treatment finally
leading to hyperalgesia.
Much less is known about the role of TLR4 in the
periphery. In our studies i.pl. injection of LPS elicits a
transient dose-dependent mechanical and thermal
antinociceptive effect blocked by a TLR4 antagonist.
This is followed in the later phase by a drop in thermal
and mechanical nociceptive thresholds. This second
phase of hyperalgesia is in line with other studies dem-
onstrating that LPS elicits hyperalgesia in rats in naïve
animals [45]. Similarly, in healthy volunteers, activa-
tion of TLR4 by endotoxin caused significant increase
in capsaicin-induced allodynia and hyperalgesia follow-
ing intradermal capsaicin [46]. Intrathecal injection of
LPS in the lumbar spinal cord produces mechanical
hyperalgesia in rat hind-paws dependent on purigergic
receptors [47]. Therefore pro-versus analgesic proper-
ties of LPS seem to be dependent on the context and
the time, the anatomical location and the model used.
TAK-242 binds selectively to TLR4 and subsequently
disrupts the interaction of TLR4 with adaptor molecules,
thereby inhibiting TLR4 signal transduction and its
downstream signaling event [48]. In contrast to the
above-described studies highlighting the antinociceptive
properties of TLR-antagonists we here demonstrate that
TLR4 blockade immediately worsens thermal hyper-
algesia in inflammatory pain. Indeed, we postulate that
the proalgesic action of TAK-242 is due to peripheral
inhibition of tonic opioid peptide release. Endogenous
TLR ligands (danger associated adapter proteins,
DAMPS) are for example heat shock proteins 22, 60, 70
and 72, high-mobility group box protein B1 (released
after cell necrosis), oxidized low sensitive of lipoprotein
or fibronection in tissue repair. All of them are found in
inflamed tissue [3] and could contribute to peripheral
opioid-mediated analgesia by macrophages in inflamed tis-
sue. Furthermore TLR4 blockade worsens mechanical
hyperalgesia with a delay. This could be better explained
by effects on central sensitization. Therefore, we propose
that different peripheral and spinal mechanisms are to be
responsible for the increased hyperalgesia with TLR4
blockade.
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In late CFA inflammation monocytes/macrophages are re-
sponsible for peripheral opioid-mediated analgesia. En-
dogenous TLR4 agonists could stimulate opioid peptide
release from monocytes and contribute to inflammatory
pain control. Antiinflammatory monocytes/macrophages
seem to be more important in this respect. Taken together
we provide further evidence that both immunosuppressive
treatment – regularly used in the treatment of e.g. in auto-
immune disease – or anti-TLR4 treatment impair en-
dogenous pain control mechanisms.Methods
Animals
Animal protocols were approved by the animal care com-
mittees (Landesamt für Arbeitsschutz, Gesundheitsschutz
und Technische Sicherheit, Senate of Berlin, und Regier-
ung von Unterfranken, Germany), and are in accordance
with the International Association for the Study of Pain
[49]. Male Wistar rats weighing 180–220 g were treated as
described below under brief isoflurane anesthesia. Animals
were sacrificed using intracardial injection of a solution of
T61 (embutramide, mebezonium and tetracaine) under
isoflurane anesthesia according to national guidelines.
Nociceptive thresholds and paw volume
Mechanical nociceptive thresholds were determined using
the paw pressure algesiometer (modified Randall-Selitto
test; Ugo Basile, Comerio, Italy) as described before [50].
A blunt piston onto the dorsal surface of the hind paw ap-
plied the pressure. The pressure required to elicit paw
withdrawal was defined as the paw pressure threshold.
The average of three measurements was calculated. Treat-
ments were randomized and blinded. A decrease in the
paw pressure threshold was interpreted as pain (hyper-
algesia) whereas a rise in the paw pressure threshold was
interpreted as analgesia (antinociception).
Thermal nociceptive thresholds were measured by the
Hargreaves test as previously described [50]. The latency
(time; s) required to elicit paw withdrawal was measured
with an electronic timer (IITC Inc/Life Science, Woodland
Hills, CA, USA) after application of radiant heat to the
plantar surface of a hind paw from underneath the glass
floor with a high-intensity light bulb. The stimulus inten-
sity was adjusted to 20 s for the paw withdrawal latency in
non-inflamed paws, and a cutoff of 30 s was set to avoid
tissue damage. The average of two measurements taken
with 20 s intervals was calculated. A decrease in paw with-
drawal latency was interpreted as pain (hyperalgesia)
whereas a rise in paw withdrawal latency was interpreted
as analgesia (antinociception)
Paw volume was measured by submerging the hind
paw till the tibiotarsal joint inside the water-filledPerspex cell of a plethysmometer at the same time
points (37140, Ugo Basile, Comerio, Italy) [51].
Treatments
Rats were intraplantarly (i.pl.) injected into the right hind
paws with 150 μl CFA (Calbiochem, Darmstadt, Germany)
for 4 d. Separate groups of rats were treated with i.pl. in-
jection of LPS, naloxone (NLX) (both Sigma-Aldrich, St.
Louis, MO, USA) or TAK-242, resatorvid, a small mol-
ecule TLR4 inhibitor (MedChem Express, HY-11109,
Princeton, NJ, USA). Doses were chosen according to pilot
experiments or previous experiments [50,52].
For immunodepletion rats were treated with cyclophos-
phamide (CTX) (Baxter, Unterschleissheim, Germany) ac-
cording to an established protocol [27], because selective
monocyte/macrophages depletion using clodronate has
previously been unsuccessful [23]. Animals were injected
i.p. 3 d and 1 d before the experiment with 100 mg/kg and
50 mg/kg of cyclophosphamide as well as on day two
after CFA i.pl. This treatment results in over 90% reduc-
tion in circulating leukocytes [26]. No change in basal
nociceptive thresholds after this treatment has been ob-
served before [28].
Monocyte isolation and macrophage differentiation
Human monocytes were used because of lack of suffi-
cient quantity and purity of rat blood monocytes to be
used for in vitro stimulation [53,54]. Monocytes were
isolated from leukocyte apheresis filters of healthy
donors by magnetic cell separation using anti-CD14-
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany)
or a combined purification using anti-CD16-microbeads
immediately after harvest. Due to anonymous collection
from left over apheresis filters, no consent from donors was
necessary in line with the ethical committee of the institu-
tion. Human monocytes were cultured in RPMI (Invitro-
gen, Darmstadt, Germany) supplemented with 10% fetal
calf serum (PAA Laboratories, Cölbe, Germany), 100 μg/ml
streptomycin and 100 units/ml penicillin (both Biochrom
AG, Berlin, Germany).
CD14+ human monocytes were cultured in a density of
2 × ∁105 cells/cm2 in CellBIND surface cell culture flasks
for 6–7 days with 50 ng/ml GM-CSF to generate GM- or
M1-macrophages and 50 ng/ml M-CSF and 25 ng/ml IL-
10 to generate M- or M2-macrophges according to the lit-
erature [55].
Opioid peptide content and release
1×107 CD14+ monocytes or 0.5×107 M1 or M2 macro-
phages were stimulated with LPS (1–10 μg/ml, Sigma-
Aldrich), Pam3CSK4 (1–10 μg/ml, InvivoGen, San Diego,
USA) or ionomycin (10 μM) after preincubation with cyto-
chalasin B (dissolved in dimethyl sulfoxide, final 5 μg/ml)
for 5 min in Hank’s balanced salt solution containing the
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(10 μg/ml) and thiorphan (dissolved in dimethyl sulfox-
ide, final 25 μg/ml, all Sigma-Aldrich) [14]. Doses of
LPS, Pam3CSK4 and ionomycin were based on pilot ex-
periments and the literature [14]. In some experiments,
cells were concomitantly incubated with inhibitors: 1, 2-
Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid
tetrakis acetoxymethyl ester (BAPTA-AM, dissolved
in dimethyl sulfoxide, Calbiochem, Merck4Biosciences,
Darmstadt, Germany) is a cell-permeant Ca2+ chelator
used to control the level of intracellular Ca2+. 2-
Aminoethoxydiphenyl borate (2-APB, dissolved in di-
methyl sulfoxide, Calbiochem) inhibits IP3 receptors. In
previous experiments the solvent dimethyl sulfoxide
(maximal final concentration 1%) did not induce signifi-
cant release [14]. Supernatants were obtained after 15–
120 min stimulation in accordance with the rapid effect
of these mediators in pain behavior tests.
For the measurement of opioid peptide content 1×106
M1 and M2 macrophages were resuspended in ELISA
buffer followed by five freeze (10–20 s) - thaw (90 s) cycles
using liquid nitrogen and a 37°C water bath as well as sub-
sequent vortexing as described before [29]. After centrifu-
gation to remove unsolvable material the supernatants
containing opioid peptides were obtained. Supernatants
were stored at −20°C until further analysis by radio-
immunoassay using commercially available kits for human
β-END (Phoenix Pharmaceuticals, Burlingame, USA).
Flow cytometry
Cellular staining of monocytes or macrophages was per-
formed as previously described [50]. Single cell suspen-
sions were incubated with the following primary and
secondary antibodies (all antibodies by BD Biosciences,
Heidelberg, Germany unless stated otherwise): Macro-
phages were preincubated with Fc block (mouse anti-rat
CD32) for 5 min at 4°C, then the first antibody anti-
human, PM-2 K (10 μg/ml, AbD Serotec, Oxford, Great
Britain), anti-human 25 F9 Biotin (10 μg/ml, ebioscience,
Frankfurt, Germany) or isotype control antibodies were
added for 30 min at room temperature. After washing cells
were incubated with the second antibody for 30 min
(anti-mouse IgG1 FITC or Streptavidin PE-Cy5). TLRs
were labeled on human monocytes or macrophages
using PE conjugated anti-human-TLR2, anti-human-
TLR4 (ebioscience) or isotype control antibodies ac-
cording to manufacturer’s instructions. CD14 and CD16
were stained with FITC-conjugated anti-CD14 and PE-
conjugated anti-CD16 antibodies for 15 min (both from
Miltenyi Biotec, Bergisch Gladbach, Germany).
For tissue analysis, subcutaneous paw tissue was obtained
and digested as described before [26,56]. Cell suspension
were stained with a mouse monoclonal anti-rat-CD45-
PerCP-Cy5, anti-rat-RP-1-PE (both BD bioscience), anti-rat-CD68-FITC and anti-rat-CD163-FITC (both AbD
Serotec) and mouse monoclonal anti-rat-TLR4-PE
(Thermo Scientific Pierce Product, Bonn, Germany).
For RP-1 and CD68 double staining cells were first fixed
in paraformaldehyde and permeabilized in saponin as
previously described [26,56].
The FACS Scan acquired 10.000-20.000 FACS events.
Data analysis was performed by CellQuest software (all
BD Biosciences).
Immunofluorescence
CD14+ human monocytes were preincubated for 5 min
with cytochalasin B followed by stimulation with
10 mM ionomycin for 15 min. Cells were harvested and
centrifugated. Cell pellets of monocytes were reconsti-
tuted in 5 ml PBS, and 50,000 monocytes in suspension
were then centrifuged by a Shandon Cytospin 3 (Thermo
Shandon, Pittsburgh, PA) at 20 g for 3 min on glass slides.
Monocytes were fixed for 30 min and confocal analysis
was carried out as previously described [14,57]. Briefly,
monocytes cytospins were incubated with rabbit poly-
clonal antibodies against β-END (1:1000, Peninsula
Laboratories, Belmont, CA, USA) and subsequently with a
Texas red-conjugated goat anti-rabbit antibody. There-
after, cytospins were washed with PBS and mounted in vec-
tashield. Images were acquired on a Zeiss LSM510META
confocal laser scanning system (Zeiss AIM; Jena, Germany)
using a 63×/1.4 Plan-Apochromat or 40×/1.3 Plan-Neofluar
oil immersion objective in a series of optical sections of
about 1 μm thickness. Each experiment was repeated three
times. To demonstrate specificity of staining, the following
controls were included as mentioned in detail elsewhere: (1)
preabsorption of diluted antibody against β-END with puri-
fied β-END (Peninsula laboratories-Bachem) and (2) omis-
sion of either the primary or the secondary antibodies.
Statistical analysis
Data are presented as raw values (mean ± SEM). Data
were tested for normality and for equal variance. Nor-
mally distributed data were analyzed by t-test or paired
t-test for samples before and after treatment. If aliquots
of one sample were exposed to different conditions or
repeated measurements from one animal were taken,
One or Two Way repeated measurement (RM) ANOVA
was used. The post hoc comparisons were performed by
Student-Newman-Keuls. In case of not normally distrib-
uted data the test was performed on ranks. Differences
were considered significant if p < 0.05.Abbreviations
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